- All sections
- C - Chemistrymetallurgy
- C07D - Heterocyclic compounds
- C07D 261/18 - Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
Patent holdings for IPC class C07D 261/18
Total number of patents in this class: 318
10-year publication summary
|
36
|
33
|
20
|
27
|
28
|
22
|
11
|
22
|
7
|
5
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Theravance Biopharma R&D IP, LLC | 426 |
47 |
| Proteostasis Therapeutics, Inc. | 69 |
9 |
| The Board of Trustees of the University of Illinois | 2740 |
8 |
| Denali Therapeutics Inc. | 260 |
8 |
| F. Hoffmann-La Roche AG | 7835 |
7 |
| Sumitomo Chemical Company, Limited | 9045 |
7 |
| Incyte Corporation | 1059 |
7 |
| The Provost, Fellows, Foundation Scholars, and The Other Members of Board, of The College of The Holy and Undivided Trinity of Queen Elizabeth, Near Dublin | 176 |
7 |
| The University of Queensland | 664 |
7 |
| Boehringer Ingelheim International GmbH | 4529 |
6 |
| VALO Health, Inc. | 186 |
6 |
| Hoffmann-La Roche Inc. | 3686 |
5 |
| Cornell University | 3384 |
5 |
| Bristol-myers Squibb Company | 4812 |
4 |
| Board of Regents, The University of Texas System | 6031 |
4 |
| Epizyme, Inc. | 357 |
4 |
| Tetraphase Pharmaceuticals, Inc. | 52 |
4 |
| Theravance, Inc. | 61 |
4 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2968 |
4 |
| Vanderbilt University | 1972 |
4 |
| Other owners | 161 |